Serum Institute to supply 1 crore qHPV vaccine doses by December: Sources
Cervical cancer in India ranks as the second most frequent cancer among women aged between 15 and 44 years.;
New Delhi: Serum Institute of India has informed the Centre that it can supply 1 crore doses of its indigenously developed Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer, by December 2022, official sources said on Monday.
Prakash Kumar Singh, Director, Government and Regulatory Affairs, Serum Institute of India (SII) has written to the Union health ministry, confirming the supply of 1 crore doses of qHPV by December, 2022 under the National Vaccination Programme, they said.
Singh has mentioned in his letter that SII will supply the vaccine at affordable price, but cannot disclose the price before the online tendering process starts, they said.
The Drugs Controller General of India (DCGI) had on July 12 granted market authorisation to SII to manufacture qHPV.
The phase 2/3 clinical trial of the vaccine has been completed with the support of the Department of Biotechnology.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.